# A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct05141721/  
OnCo record `nct05141721` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing GRT-C901 in colorectal cancer, active and no longer recruiting.

## Summary

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer is a phase 2/3 interventional study registered as NCT05141721, led by Seattle Project, and active but no longer recruiting on the registry. Official title: A Phase 2/3, Randomised, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer. Planned enrolment is 700 participants (estimated). The study started in 2022-02-12 and primary completion is expected in 2027-03. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT05141721
- Phase: 2/3
- Setting: A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
- Sponsor: Seattle Project
- Enrolled: 700

## Sources

- ClinicalTrials.gov NCT05141721: https://clinicaltrials.gov/study/NCT05141721

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [GRT-C901](https://onco.cc/drugs/grt-c901/), [GRT-R902](https://onco.cc/drugs/grt-r902/)

---
JSON: https://onco.cc/api/v1/entities/nct05141721.json